Cooley advised Personalis, a company transforming the active management of cancer through breakthrough personalized testing, on its expanded commercial relationship with Tempus AI, including an equity investment by Tempus into Personalis. Personalis and Tempus agreed in November 2023 to collaborate and bring ultra-sensitive minimal residual disease (MRD) testing to market and have now agreed to accelerate their efforts.
Key deals, decisions + trends
Close